ADIL
Adial Pharmaceuticals, Inc.0.2640
-0.0102-3.72%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
7.04MP/E (TTM)
-Basic EPS (TTM)
-0.60Dividend Yield
0%Recent Filings
8-K
10-Q
8-K
FDA endorses AD04 Phase 3 design
Adial Pharmaceuticals received final FDA minutes from its July 29, 2025, End-of-Phase 2 meeting, endorsing the adaptive Phase 3 trial design for AD04 in treating Alcohol Use Disorder among heavy drinkers with select genotypes. The FDA affirmed core elements like biomarker stratification, moderate-to-severe AUD criteria, and primary endpoints of zero heavy drinking days in months 5-6, while recognizing AUD as an unmet need. This alignment accelerates AD04's path to registration. Forward-looking statements highlight execution risks in trials and partnerships.
8-K
Nasdaq grants bid price extension
Adial Pharmaceuticals received a 180-day extension from Nasdaq on September 2, 2025, to regain compliance with the $1.00 minimum bid price rule, pushing the deadline to March 2, 2026, after missing the initial September 1 target. The company plans to monitor its stock price closely and may enact a reverse stock split if needed to avoid delisting. Trading continues uninterrupted under ADIL. Yet failure looms if the bid doesn't hit $1.00 for 10 straight days.
8-K
Adial's FDA milestone advances AD04
Adial Pharmaceuticals reported Q2 2025 results, highlighting a successful End of Phase 2 FDA meeting that secured agreement on AD04's Phase 3 trial design for Alcohol Use Disorder, including targeted patient subgroups via machine learning to boost success odds. Cash climbed to $5.9 million from $2.4 million, funding operations into Q2 2026, while R&D expenses dropped 28% and net loss narrowed to $2.0 million from $2.5 million year-over-year. Regaining Nasdaq compliance strengthens footing. Yet risks loom in trial execution.
ACET
Adicet Bio, Inc.
0.47-0.03
ADAG
Adagene Inc.
1.90+0.23
ADXN
Addex Therapeutics Ltd
7.56+0.55
ALZN
Alzamend Neuro, Inc.
2.16+0.05
ANL
Adlai Nortye Ltd.
1.64+0.15
ANRO
Alto Neuroscience, Inc.
17.10+0.07
ATHE
Alterity Therapeutics Limited
3.07+0.06
IGC
IGC Pharma, Inc.
0.34+0.00
LBRX
LB Pharmaceuticals Inc
19.82-0.04
TIL
Instil Bio, Inc.
11.25+0.13